Lipocine Inc (LPCN) Stock Price, Quote & News

Company Profile

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1111 (TLANDO XR), a next-generation long-acting oral product candidate for TRT; LPCN 1148, a novel prodrug of testosterone and testosterone...

Industry: Biotechnology

Sector: Healthcare

Phone: 801 994 7383

Fax: 801 994 7388

Website: www.lipocine.com

Address:

675 Arapeen Drive, Suite 202, Salt Lake City, United States

Pedelco Oct. 27 at 4:51 PM

$LPCN come ✌️

0 · Reply

veseli Oct. 24 at 2:37 PM

$LPCN Yesterdays prophecy coming true

2 · Reply

veseli Oct. 15 at 7:28 PM

$LPCN Dead in the water 🤷

2 · Reply

dbatech99 Oct. 13 at 7:59 PM

$AMD Here are the only 2 stinkers I have... $PTON and $LPCN I don't have a large position of each... but I've been so patient and both have sucked ass forever. Peloton... I have considered a loss. It's never going to get back to where I paid for it... I don't see it. I paid like 35 bucks for it and I thought it was a good buy (thanks Motley freaking Fool:( ). LPCN has all the promise... but it's been promising for years and it looks like a math limit bound by zero. I have mentally checked out on both.

1 · Reply

CalculatedSwing Oct. 13 at 5:11 PM

$GLMD 🚀 flexing $20.7M cash fortress after Q2 build-up, slamming 50% into crypto staking & yields for epic degen alpha! Aramchol's biomarker unlock = multi-BILLION$ NASH expansion catalyst, Oct AGM $AKBA $IMUX $LPCN $OCGN – ready to rip! Strap in! 💰🧬📈 #BiotechBulls #DegenMed

2 · Reply

Walkadon Oct. 12 at 6:45 AM

$LPCN Do they have a deal with Teledyne FLIR for all the police helicopter night vision FLIR systems ? That could be a huge market for them.

1 · Reply

Geraldbeak Oct. 8 at 1:37 AM

$LPCN The Q4 DSMB is the catalyst to watch for in the near term. No other things matter being that no partnership is likely without a compelling argument. This will be an argument if positive.

1 · Reply

brunoq14 Oct. 7 at 11:42 AM

$LPCN Too heavily invested elsewhere to buy much here at present. Only 3000 shares @ 3.03. I sold all the rest of my shares over $10 when it spiked.

1 · Reply

Tothemoonemoji Oct. 6 at 10:01 PM

$LPCN Volume starting to creep up. Over 300k shares traded today, compared to our usual 5-10k.

1 · Reply

chiefcoho Oct. 6 at 1:54 AM

$LPCN let’s break the ceiling!!🙏🙏🙏🙏🙏🙏🙏

0 · Reply

Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD)

Sep 5, 2025, 4:30 PM EDT - 7 weeks ago

Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference

Aug 26, 2025, 8:00 AM EDT - 2 months ago

Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025

Aug 5, 2025, 8:00 AM EDT - 2 months ago

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025

Jun 26, 2025, 8:00 AM EDT - 4 months ago

Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression

Jun 23, 2025, 8:00 AM EDT - 4 months ago

Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025

Jun 9, 2025, 8:00 AM EDT - 5 months ago

Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada

May 22, 2025, 8:00 AM EDT - 5 months ago

Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology

May 14, 2025, 8:00 AM EDT - 5 months ago

Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase

May 8, 2025, 8:00 AM EDT - 6 months ago

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025

May 6, 2025, 8:00 AM EDT - 6 months ago

Lipocine Announces License and Supply Agreement for TLANDO® in Brazil

Mar 26, 2025, 8:00 AM EDT - 7 months ago

Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154

Mar 13, 2025, 8:00 AM EDT - 8 months ago

Lipocine Announces Financial Results for the Full Year Ended December 31, 2024

Mar 12, 2025, 8:00 AM EDT - 8 months ago

Lipocine Announces FDA Labeling Changes for Testosterone Products

Feb 6, 2025, 8:00 AM EST - 9 months ago

Lipocine Receives Updated Regulatory Guidance on LPCN 1154

Dec 17, 2024, 8:00 AM EST - 11 months ago

FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis

Nov 18, 2024, 8:00 AM EST - 1 year ago

Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session

Nov 7, 2024, 8:00 AM EST - 1 year ago

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea

Oct 10, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results

Oct 8, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries

Oct 2, 2024, 8:00 AM EDT - 1 year ago

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®

Aug 27, 2024, 8:00 AM EDT - 1 year ago

Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024

Jun 25, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study

Jun 10, 2024, 8:00 AM EDT - 1 year ago

Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024

May 9, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024

May 8, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024

May 1, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154

Apr 11, 2024, 7:00 AM EDT - 1 year ago

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity

Mar 28, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis

Mar 25, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154

Mar 7, 2024, 8:00 AM EST - 1 year ago

Lipocine Announces Financial Results for the Full Year Ended December 31, 2023

Mar 6, 2024, 8:00 AM EST - 1 year ago

Lipocine to Present at 36th Annual Roth Conference

Feb 6, 2024, 8:00 AM EST - 1 year ago

Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154

Feb 2, 2024, 8:00 AM EST - 1 year ago

Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals

Jan 18, 2024, 8:00 AM EST - 1 year ago

Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada

Dec 19, 2023, 8:00 AM EST - 2 years ago

Lipocine to Present at Biotech Showcase 2024

Nov 13, 2023, 2:45 PM EST - 2 years ago

Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023

Nov 8, 2023, 8:00 AM EST - 2 years ago

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023

Nov 1, 2023, 8:00 AM EDT - 2 years ago

Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023

Oct 26, 2023, 8:00 AM EDT - 2 years ago

Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression

Oct 23, 2023, 7:00 PM EDT - 2 years ago

Lipocine to Present at the H.C. Wainwright Annual NASH Investor Conference

Sep 19, 2023, 4:05 PM EDT - 2 years ago

Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference

Aug 10, 2023, 8:00 AM EDT - 2 years ago

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023

Jul 27, 2023, 6:30 AM EDT - 2 years ago

LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis

Jun 14, 2023, 8:00 AM EDT - 2 years ago

Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference

Jun 7, 2023, 8:00 AM EDT - 2 years ago

Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023

Pedelco Oct. 27 at 4:51 PM

$LPCN come ✌️

0 · Reply

veseli Oct. 24 at 2:37 PM

$LPCN Yesterdays prophecy coming true

2 · Reply

veseli Oct. 15 at 7:28 PM

$LPCN Dead in the water 🤷

2 · Reply

dbatech99 Oct. 13 at 7:59 PM

1 · Reply

CalculatedSwing Oct. 13 at 5:11 PM

2 · Reply

Walkadon Oct. 12 at 6:45 AM

$LPCN Do they have a deal with Teledyne FLIR for all the police helicopter night vision FLIR systems ? That could be a huge market for them.

1 · Reply

Geraldbeak Oct. 8 at 1:37 AM

$LPCN The Q4 DSMB is the catalyst to watch for in the near term. No other things matter being that no partnership is likely without a compelling argument. This will be an argument if positive.

1 · Reply

brunoq14 Oct. 7 at 11:42 AM

$LPCN Too heavily invested elsewhere to buy much here at present. Only 3000 shares @ 3.03. I sold all the rest of my shares over $10 when it spiked.

1 · Reply

Tothemoonemoji Oct. 6 at 10:01 PM

$LPCN Volume starting to creep up. Over 300k shares traded today, compared to our usual 5-10k.

1 · Reply

chiefcoho Oct. 6 at 1:54 AM

$LPCN let’s break the ceiling!!🙏🙏🙏🙏🙏🙏🙏

0 · Reply

brunoq14 Oct. 5 at 10:25 AM

$LPCN There is an announcement at the trial website about effects of the government shutdown.

1 · Reply

Tothemoonemoji Oct. 4 at 11:30 PM

$LPCN Afterhours buys yesterday looked pretty decent, almost a 10k share buy at 3.60. I say we get a significant move up this week. Whether it means anything has changed beyond speculation remains to be seen

1 · Reply

Boknow Oct. 3 at 4:56 PM

$LPCN In my opinion, $10 or more by January, maybe before, we have a few things going along in the pipeline. Let’s go LPCN

2 · Reply

aah98a Oct. 3 at 4:29 PM

$LPCN I Love it! I hope we can run this over $10 a share. Does anyone know when is the safety Board meeting?

1 · Reply

Boknow Oct. 3 at 3:23 PM

$LPCN This is priming for a takeoff

0 · Reply

ITF Oct. 2 at 9:10 AM

$LPCN have we started the climb?

2 · Reply

prismmarketview Sep. 30 at 7:30 PM

(NASDAQ: $LPCN) Lipocine has announced it is advancing its Phase 3 trial for LPCN-1154, targeting postpartum depression. The move underscores growing confidence in the drug’s therapeutic potential and highlights mental health innovation in women’s health. https://prismmarketview.com/lipocine-advances-phase-3-trial-of-lpcn-1154-for-postpartum-depression/

0 · Reply

JoJo2024 Sep. 30 at 1:51 PM

Became aware of $LPCN because I owned $SAGE. Since SAGE has the patent rights to brexanolone, how does this impact LPCN? Does lipocine have to license/pay Supernus for using brexanolone?

1 · Reply

brunoq14 Sep. 29 at 5:25 PM

$LPCN Down to about six months, right? Results anticipated in Q2, 26. Now three months past first dosing.

1 · Reply

upNupAlways3 Sep. 25 at 4:11 PM

$LPCN time to walking down for accumulation for Data in Q4!!! Fukn market makers!!!

0 · Reply

Tothemoonemoji Sep. 25 at 12:29 AM

$LPCN

1 · Reply

HoHoHoHum Sep. 19 at 1:12 PM

$LPCN not participating in the rally?

1 · Reply

Market Cap	15.72M
Revenue (ttm)	11.20M
Net Income (ttm)	10,000.00
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.09%
Debt to Equity Ratio	0.00

Volume	26,700
Avg Vol	33,576
Day's Range	N/A - N/A
Shares Out	5.42M
Stochastic %K	33%
Beta	1.29
Analysts	Sell
Price Target	$7.38